Evidence map›Paper›PMID 35908251›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2022

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.

Oskar Hansson, Rebecca M Edelmayer, Adam L Boxer, Maria C Carrillo, Michelle M Mielke, Gil D Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Charlotte E Teunissen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 397 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
397citing papers in PubMed, 15 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

397 citing papers in PubMed, 15 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Guideline
  10. Pooled it
  11. Guideline
  12. Sex differences inFrontiers in dementia · 2025
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Guideline
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

337 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Oskar HanssonClinical, Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
Rebecca M EdelmayerAlzheimer's Association, Chicago, Illinois, USA.
Adam L BoxerDepartment of Neurology, University of California San Francisco, Memory and Aging Center, San Francisco, California, USA.
Maria C CarrilloAlzheimer's Association, Chicago, Illinois, USA.
Michelle M MielkeDepartment of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Gil D RabinoviciDepartment of Neurology, University of California San Francisco, Memory and Aging Center, San Francisco, California, USA.
Stephen SallowayDepartments of Neurology and Psychiatry, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Reisa SperlingCenter, for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Charlotte E TeunissenNeurochemistry, Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, the Netherlands.

Funding

The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI WILLIAM W SEELEY · 2019 to 2026
$120.9M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Vascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI REISA A. SPERLING · 2010 to 2026
$50.2M
Combination anti-amyloid therapy for preclinical Alzheimer's diseaseR01AG061848 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AISEN, PAUL S., JOHNSON, KEITH A. · 2018 to 2024
$43.9M
Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's DiseaseR01AG053798 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AISEN, PAUL S., CUMMINGS, JEFFREY L. · 2017 to 2022
$39.4M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8M
The A3 Study: Ante-Amyloid Prevention of Alzheimer's diseaseR01AG054029 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., JOHNSON, KEITH A. · 2016 to 2023
$20.9M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9M
NIA NIH HHS P01 AG019724NIA NIH HHS P01 AG036694NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG053798NIA NIH HHS R01 AG054029NIA NIH HHS R01 AG061848NIA NIH HHS R01 AG063689NIA NIH HHS R35 AG072362NIA NIH HHS R56 AG057195NIA NIH HHS U01 AG045390NIA NIH HHS U01 AG057195NIA NIH HHS U19 AG063911NIA NIH HHS U24 AG057437NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We already now recommend use of BBMs as (pre-)screeners to identify individuals likely to have AD pathological changes for inclusion in trials evaluating disease-modifying therapies, provided the AD status is confirmed with positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. We also encourage studying longitudinal BBM changes in ongoing as well as future interventional trials. However, BBMs should not yet be used as primary endpoints in pivotal trials. Further, we recommend to cautiously start using BBMs in specialized memory clinics as part of the diagnostic work-up of patients with cognitive symptoms and the results should be confirmed whenever possible with CSF or PET. Additional data are needed before use of BBMs as stand-alone diagnostic AD markers, or before considering use in primary care.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBiomarkersHumansLongitudinal StudiesPeptide FragmentsPositron-Emission TomographyPrognosistau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAlzheimer's diseaseappropriate use recommendationsblood-based biomarkersdiagnosisprognosis

Identifiers

PMID35908251
PMCPMC10087669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.